Understanding how certain cancer drugs affect the heart to improve treatment outcomes.
Official title: Defining kinase interaction pathways to enhance anti-cancer efficacy and minimize associated morbidities of kinase inhibitor drugs.
Funded at Stanford University · NIH-10896175 · Data updated 2026-11-12
This study is looking at how certain cancer drugs called Tyrosine Kinase Inhibitors (TKIs) affect heart health, with the goal of finding ways to make these treatments safer for cancer patients while still being effective.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $153,954 |
| NIH project number | 5K99CA279895-02 |
| Project ID | NIH-10896175 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients, particularly those with Chronic Myeloid Leukemia (CML), who are being treated with Tyrosine Kinase Inhibitors.
✕Less likely to help
Patients who are not undergoing treatment with Tyrosine Kinase Inhibitors or those with conditions unrelated to the cardiovascular effects of cancer treatments may not benefit from this research.
What this research studies
This research investigates the effects of Tyrosine Kinase Inhibitors (TKIs), which are commonly used cancer treatments, on cardiovascular health. It aims to identify the specific kinase interactions that lead to both the anti-cancer effects and the cardiovascular side effects of these drugs. By using advanced pharmacological and genetic techniques, the study seeks to map out the signaling networks involved in these processes, potentially leading to safer treatment options for cancer patients. The findings could help in developing new drug analogues that minimize harmful side effects while maintaining efficacy against cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that reduce harmful cardiovascular side effects, enhancing the quality of life for patients.
How similar studies have gone: Previous research has shown promise in understanding kinase interactions and their effects on cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Hnatiuk Hnatiuk, Anna Pavlovna — Stanford University
- Study coordinator: Hnatiuk Hnatiuk, Anna Pavlovna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.